Isabelle Madelaine
- Oncology top 5%
- CAR-T cell therapy research 15
- Cancer Immunotherapy and Biomarkers 7
- Cancer Treatment and Pharmacology 5
- Dermatology top 5%
- Virology top 10%
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 10
- Toxicology top 5%
-
- Safe Handling of Antineoplastic Drugs 9
-
- Pharmaceutical Practices and Patient Outcomes 8
-
- Chronic Lymphocytic Leukemia Research 7
-
- Melanoma and MAPK Pathways 6
- Co-authors
- Célèste LebbéCatherine ThiéblemontJean‐Michel MolinaJean Marc ExtraDominique FargeA. Mathieu-BouéM ForniM. Bagot
- Cited by
- OncologyDermatologyVirology
- Journals
- Therapeutic Drug Monitoring (3 papers)Melanoma Research (3 papers)The Journal of Infectious Diseases (2 papers)
- Partner nations
- FranceUnited StatesSweden
In The Last Decade
Isabelle Madelaine
67 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 96
- Oncology 534
- Dermatology 152
- Virology 75
- Pathology and Forensic Medicine 212
- Toxicology 38
Countries citing papers authored by Isabelle Madelaine
This map shows the geographic impact of Isabelle Madelaine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Madelaine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Madelaine more than expected).
Fields of papers citing papers by Isabelle Madelaine
This network shows the impact of papers produced by Isabelle Madelaine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Madelaine. The network helps show where Isabelle Madelaine may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Isabelle Madelaine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 1 | |
| 6 | 2023 | 6 | |
| 7 | 2023 | 0 | |
| 8 | 2022 | 43 | |
| 9 | 2022 | 20 | |
| 10 | 2022 | 2 | |
| 11 | 2021 | 6 | |
| 12 | 2021 | 8 | |
| 13 | 2021 | 12 | |
| 14 | 2021 | 6 | |
| 15 | 2020 | 6 | |
| 16 | 2018 | 8 | |
| 17 | 2017 | 34 | |
| 18 | 2013 | 15 | |
| 19 | Cancer du sein : actualités diagnostiques et thérapeutiques | 2003 | 1 |
| 20 | New cytotoxic drugs in clinical development. | 1991 | 1 |
About Isabelle Madelaine
Isabelle Madelaine is a scholar working on Occupational Therapy, Geriatrics and Gerontology and Family Practice, having authored 73 papers that have together received 1.2k indexed citations. Recurring topics across this work include CAR-T cell therapy research (15 papers), Lymphoma Diagnosis and Treatment (10 papers), Safe Handling of Antineoplastic Drugs (9 papers), Pharmaceutical Practices and Patient Outcomes (8 papers), Chronic Lymphocytic Leukemia Research (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Melanoma and MAPK Pathways (6 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Oncology (534 citations), Dermatology (152 citations) and Virology (75 citations). Isabelle Madelaine has collaborated with scholars based in France, United States and Sweden. Frequent co-authors include Célèste Lebbé, Catherine Thiéblemont, Jean‐Michel Molina, Jean Marc Extra, Dominique Farge, A. Mathieu-Boué, M Forni, M. Bagot, G G Chabot and R. Bugat. Their work appears in journals such as Therapeutic Drug Monitoring, Melanoma Research, The Journal of Infectious Diseases, Cytotherapy and British Journal of Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.